Leap Therapeutics downgraded by Robert W. Baird with a new price target

1/29/25 7:15:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LPTX

Date	Price Target	Rating	Analyst
1/29/2025		Buy → Neutral	H.C. Wainwright
1/29/2025	$9.00 → $1.25	Outperform → Neutral	Robert W. Baird
6/28/2024	$8.00	Buy	Rodman & Renshaw
10/4/2021	$6.00	Buy	Mizuho
9/14/2021	$3.00 → $4.00	Outperform	Raymond James